Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Phase 1/2
104
about 2.6 years
18+
1 site in NC
What this study is about
Researchers are testing the best dose of a treatment for people with advanced basal-like pancreatic cancer. The goal is to see if this combination of drugs is safe, effective, and well-tolerated in these patients. The trial will also follow some patients with classical subtypes who are treated per standard of care on oxaliplatin-based triplet chemotherapy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Erlotinib
- 2.Take Folfirinox
- 3.Take Gemcitabine
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
erlotinib, chemotherapy, gemcitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules)
oral (Oral Tablet), infusion, injection (Injection)
Primary: Adverse Events per Common Terminology Criteria for Adverse Events (NCI-CTCAE), Dose-limiting toxicity (DLT), Overall survival- classical metastatic pancreatic adenocarcinoma, Progression-free survival
Secondary: Overall survival in subjects with basal-like metastatic pancreatic adenocarcinoma, Progression-free survival (PFS) in subjects with classical pancreatic adenocarcinoma, The number of Adverse Events (AEs) in subjects with basal like pancreatic carcinoma, The number of Adverse Events (AEs) in subjects with classical pancreatic adenocarcinoma, The objective response in subjects with classical pancreatic adenocarcinoma, The objective response rate- basal-like pancreatic carcinoma
Oncology